Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial

What Was Tested

This randomized controlled trial paper looks at Liraglutide.

To evaluate serum amylase and lipase levels and the rate of acute pancreatitis in patients with type 2 diabetes and high cardiovascular risk randomized to liraglutide or placebo and observed for 3.5-5.0 years.

Who Took Part

According to the abstract, 9,340 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

A total of 9,340 patients with type 2 diabetes were randomized to either liraglutide or placebo (median observation time 3.84 years).

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.

As a double-blind Liraglutide study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Liraglutide could be set against what happens without it.

Fasting serum lipase and amylase were monitored.

Acute pancreatitis was adjudicated in a blinded manner.

What Was Measured

The subject headings attached to it are Acute Disease, Amylases, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Lipase and Liraglutide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide in 9,340 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Diabetes care), a journal based in United States.

More context: the Liraglutide compound page.